Yeasen Biotechnology is a leading biotechnology company specializing in protein engineering and directed evolution technology. Since its establishment in 2014, Yeasen has been dedicated to the advancement of molecular enzymes and proteins within the life science sector. Leveraging our proprietary materials, we have undertaken the development of enzyme and reagents across three key categories: molecules, proteins, and cellular biology. These products cater to the demands of the life science research, molecular diagnostics, and biopharmaceutical industries. Over more than 10 years, Yeasen has evolved into a distinguished international high-tech enterprise, boasting self-reliant research and development as well as manufacturing capabilities.
YAMAHA MOTOR CO., LTD.
Yamaha Motor strives to offer our customers around the world products and services that bring joy and unexpected exhilaration that enriches their lives with new fulfillment, in harmony with society and the environment. One of our newer endeavors is in the healthcare domain, offering the CELL HANDLER2 – an automated cell imaging/analysis/transfer system. Yamaha Motor’s sophisticated technologies support researchers undertaking various challenges in cell and cancer research.
Xellar Biosystems
Xellar Biosystems is a Wet Artificial Intelligence (AI) biotechnology company, combining machine learning and AI with large-scale wet-lab experiments, tackling the most challenging problem in modern drug discovery – harnessing the complexity of human biology to accelerate drug discovery and development.
XDemics
XDemics is a biotechnology company pioneering next-generation cell culture and bioproduction technologies that dramatically improve the efficiency and scalability of life science workflows. We address one of the most critical bottlenecks in biomedical research and manufacturing: the ability to reliably grow high-quality mammalian cells at scale, including CAR-T, MSCs, stem cells, and so much more! At the core of XDemics’ platform is our patented High Density Cell Respiration™ technology, which enables cells to grow at 10–100× higher densities beyond conventional methods by optimizing oxygen delivery and cellular microenvironments. This breakthrough drives significant gains in productivity, reproducibility, and cost efficiency, accelerating timelines from discovery to commercialization. XDemics’ solutions span from advanced cultureware to scalable bioreactor systems, supporting applications across cell and gene therapies, monoclonal antibody (mAb) production, and oncolytic virus manufacturing. By enabling seamless scale-up from benchtop research to industrial production, we empower scientists and biopharma organizations to bring innovative therapies to market faster and more affordably. Through our platform, XDemics is redefining bioproduction, unlocking higher yields, lower costs, and broader access to next-generation medicines.
Wuhan Healthgen Biotechnology Corp.
Wuhan Healthgen Biotechnology Corp. (Stock Code: 668765) is a molecular pharmaceutical company specializing in the development, manufacturing, and marketing of recombinant proteins. Using its proprietary OryzHiExp platform, Healthgen achieves high-yield expression of proteins and peptides in rice grains. Its flagship product, Recombinant Human Serum Albumin (OsrHSA), is a critical reagent used in cell culture, medical devices, biopharmaceutical excipients, and cosmetic additives.
Wasatch BioLabs
Wasatch BioLabs (WBL) is an independent biotechnology company with a disruptive approach to research and diagnostics. We are an R&D and Oxford Nanopore Technologies-certified laboratory that offers DNA and RNA sequencing services to researchers and clinical service providers. WBL’s solutions span both standard Oxford Nanopore Technologies sequencing services as well as proprietary methylation sequencing services built off of WBL’s NESSI-Seq platform, that expand the capabilities of the nanopore platform. | Wasatch BioLabs, a leading NGS sequencing service provider, harnesses advanced native-read sequencing and streamlined R&D workflows—translating breakthrough discovery into real-world outcomes.
VivoTex LLC
VivoTex offers 3D printed microfiber scaffolds that are engineered to help researchers replicate tissue models more effectively than other currently available 3D scaffolds, matrices, or bioinks. Our founders co-invented a technology called melt electrowriting (MEW) that allows for more precise control over the cell micro-environment, accelerating cell growth, enhancing cell-to-cell communication, and boosting cell viability to improve outcomes, speed, and reproducibility.
VivoxBio, Inc
Our approach combines clinically relevant humanized cancer models, real-time imaging, and precision oncology techniques to: Accelerate drug development timelines Enhance screening efficiency Develop innovative tumor-targeting and monitoring solutions We strive to transform cancer into a manageable chronic condition by disrupting its evolutionary mechanisms, offering renewed hope to patients globally.
VION Biosciences
VION Biosciences is a specialized life science platform company focused on manufacturing and supplying mission-critical reagents, specialty chemicals, and assay kits for research, diagnostics, and drug development. We provide integrated, high-quality materials—including lipid nanoparticles and custom formulations—from discovery to commercialization. VION Biosciences aims to accelerate scientific research and clinical testing through innovation and flexible manufacturing solutions.
VectorBuilder Inc.
VectorBuilder is a revolutionary online platform that provides researchers with a one-stop solution for all vector design, custom cloning, and virus packaging needs. VectorBuilder also offers many molecular biology services such as stable cell line generation, library construction, and exceptional GMP facilities for a wide range of clinical applications.